Communicating Early Treatment Benefits and Navigating VMAT2 Inhibitor Dosing in Tardive Dyskinesia

In 'Communicating Early Treatment Benefits and Navigating VMAT2 Inhibitor Dosing in Tardive Dyskinesia,' the expert psychiatry pharmacists examined the following critical questions:

What communication strategies help patients understand the benefits of starting tardive dyskinesia (TD) treatment early?

How do dosing regimens differ between vesicular monoamine transporter 2 (VMAT2) inhibitors and why is this important in special patient populations?

Led by the moderator, the panelists discussed effective communication strategies for helping patients understand the benefits of early TD treatment, emphasizing the value of tangible, patient-level handouts, keeping messaging simple and tailored to each patient's level of functionality, and leveraging existing resources from organizations such as the National Alliance on Mental Illness (NAMI) and TDhelp.org. Jamie Kneebusch and Farah Khorassani highlighted the role of motivational interviewing and analogies to more familiar chronic conditions, such as diabetes, to help patients grasp the importance of early intervention and the potential irreversibility of TD. The panelists then compared dosing regimens between valbenazine and deutetrabenazine, noting differences in titration schedules, drug interaction considerations, and formulation flexibility, while emphasizing that once-daily dosing options are generally associated with higher adherence rates compared with twice-daily regimens.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Differentiating VMAT2 Inhibitors: Long-Term Management and Safety Data That Builds Confidence,' features the panelists advancing their conversation on tardive dyskinesia and focusing on the factors that differentiate VMAT2 inhibitors in long-term management, as well as how safety and tolerability data can support clinician confidence in prescribing these therapies.